



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A61K 31/095, 49/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 93/14746 (43) International Publication Date: 5 August 1993 (05.08.93)</p>
<p>(21) International Application Number: PCT/US93/01237 (22) International Filing Date: 3 February 1993 (03.02.93) (30) Priority data: 830,150 3 February 1992 (03.02.92) US Not furnished 12 December 1992 (12.12.92) US (71) Applicant: SCHWIMMER, Adolph [US/US]; 20 W. 65th Street, New York, NY 10023 (US). (71)(72) Applicant and Inventor: RUBIN, David [US/US]; 8949 Montrose Way, San Diego, CA 92122 (US). (74) Agent: KORNBAU, Anne, M.; Browdy and Neimark, 419 Seventh Street, N.W., Ste. 300, Washington, DC 20004 (US).</p>		<p>(81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: METHOD AND COMPOSITIONS FOR INHIBITING TUMOR CELL METABOLISM</p>		
<div style="text-align: center; margin: 20px 0;"> $\begin{array}{c} \text{S} \\ \\ \text{R}^1 \text{R}^2 \text{CS}^- \text{M}^+ \end{array} \quad (\text{I}) \qquad \begin{array}{c} \text{S} \\ \\ -\text{SCNR}^3 \text{R}^4 \end{array} \quad (\text{II})$ </div>		
<p>(57) Abstract</p> <p>The metabolism of tumor cells which have β-glucuronidase activity is inhibited by administering to a patient a conjugate of glucuronic acid and a thiocarbamate compound of formula (I) wherein R¹ and R² are selected from the group consisting of C₁-C₆ alkyl and C₁-C₆ cycloaliphatic, and M is selected from the group consisting of hydrogen, an electropositive, ionically bonded metal, and the radical (II) and R³ and R⁴ are selected from the group consisting of C₁-C₆ alkyl and C₁-C₆ cycloaliphatic groups.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

**METHOD AND COMPOSITIONS FOR INHIBITING TUMOR
CELL METABOLISM**

5 **Field of the Invention**

The present invention is directed to a method and composition for treating tumors exhibiting β -glucuronidase activity, and, more specifically, to a method and composition for treating tumors exhibiting β -glucuronidase activity by preventing metabolism of tumor cells.

This application is a continuation-in-part of Serial No. 07/830,150, filed February 3, 1992, the entire contents of which are incorporated herein.

15

Background of the Invention

Control of cell growth is one of the most important aspect of an animal's physiology. The cells of an adult must divide frequently enough to allow tissues to remain in a steady state, and division must be stimulated at wounds or when special requirements are placed on a tissue. There must be many circulating cell-specific factors that signal individual cell types whether to divide or not. However, uninhibited cell growth results in tumors.

Malignant tumors can be differentiated from benign tumors by two major characteristics: invasiveness and spread. Malignant tumors do not remain localized and encapsulated, as do benign tumors. The malignant tumors invade surrounding tissues, invade the body's circulatory system, and set up areas of proliferation away from the site of their original appearance. Cancer cells have abnormal and unstable numbers of chromosomes, as well as many chromosomal abnormalities.

One of the major limitations of effective cancer chemotherapy is toxicity to normal tissues. Agents that are effective killers of neoplastic cells are usually also

- 2 -

detrimental to normal cells, particularly to rapidly proliferative cells of the gastrointestinal tract and bone marrow. Some attempts have been made to deliver chemotherapeutics more directly to cancer cells by the use of antibody-drug conjugates, as described by Hurwitz in Optimization of Drug Delivery, Alfred Benzon Symposium 17, Editors, Hans Bundgaard et al., Munksgaard, Copenhagen, 1982. However, in this case, antibodies specific to the tumor must be used in order to provide the specificity of delivery required for this technique to be useful. More importantly, however, there has been no demonstration that this approach would be feasible in solid tumor systems, particularly in those which have a tendency to metastasize.

Nickel and certain of its diverse compounds are well known to be carcinogenic, and nickel carbonyl is the most carcinogenic of the inhaled nickel compounds. Inhalation of nickel carbonyl will produce lung cancer within a period of two years in Wistar rats, a species unusually resistant to lung cancer, and nickel subsulfide appears to have the greatest carcinogenic potential of the inorganic nickel compounds when injected into striated muscle or testes of experimental animals. Various soluble salts of diethyldithiocarbamate have been found to exert a detoxifying effect against the acute inhalation of lethal quantities of nickel carbonyl by warm-blooded animals, Sunderman et al., Annals of Clinical and Laboratory Science 14 (1): 1-9, 1984. The soluble salts of diethyldithiocarbamate were found to inhibit carcinogenesis in rats chronically subjected to nickel subsulfide by muscular implantations (Sunderman et al., *op. cit.*). The diethyldithiocarbamates were found to bind nickel successfully, and met the criteria of a clinically useful metallic chelating agent: (1) non-toxic; (2) relatively specific for the metal to be mobilized; and (3) capable of forming a stable excretable complex of the metal.

- 3 -

Sodium diethyldithiocarbamate has also been used as a potentiating agent for levamisole in treating cancer, Renoux, TIPS 248-249, 1981. Sodium diethyldithiocarbamate has been found, in high doses such as above 200 mg/kg, to potentiate barbital sleep, inhibit dopamine beta-hydroxylase and depress brain norepinephrine levels. At doses of up to 600 mg/kg levels, sodium diethyldithiocarbamate induces retrograde amnesia of trained passive avoidance and cerebral seizure in the rat. This compound also prevents the development of chemically-induced diabetes. As a chelating agent, sodium diethyldithiocarbamate is used in the treatment of metal poisoning without toxic or untoward side effects at daily doses of 30-50 mg/kg body weight.

There has been no evidence of carcinogenicity of the diethyldithiocarbamate when administered in the feed for 104-109 weeks to rats and mice. The incidence of spontaneous tumors was lower in the dosed groups than in the corresponding control group. Additionally, the diethyldithiocarbamate was found to exert a protective effect against a variety of chemically-induced malignant tumors, and against ionizing radiation.

When used in immunostimulant doses of about 0.5-25 mg/kg, diethyldithiocarbamate evidences a unique influence on the immune system in inducing the recruitment of T cells for undifferentiated precursor cells. This influence is mediated through the increased synthesis of hormone-like factors active on the T-cell lineage. The diethyldithiocarbamate induces T cells to generate enhanced levels of cytotoxic activity and responses to alloantigens, macrophages and monocytes to participate in delayed-type hypersensitivity, resting T cells to develop suppressive activities, and B cells to secrete antibodies of the IgG class. These activities are probably associated with an increase in the number of Lyt-1+ T cells which provide the signal for help to increase the response of other cell subsets when needed.

- 4 -

Diethyldithiocarbamate is devoid of direct influence on B cells, nonspecific polyclonal activity, and in vitro augmenting effects, and has no sensitizing or pyrogenic influence.

5 Perchellet et al. reported in Cancer Research
47: 6302-6309, 1987, that diethyldithiocarbamate injected
intraperitoneally inhibits 12-O-tetradecanoylphorbol-13-
acetate (TPA)-decreased glutathione peroxidase and TPA-
induced ornithine decarboxylase activities in mouse
10 epidermis in vivo. Diethyldithiocarbamate is more potent
in inhibiting these effects of TPA than sixteen other
antioxidants, free radical scavengers, thiol-containing
compounds, and reduced glutathione level-raising agents,
even though some of these treatments are applied directly
15 to the TPA-treated skin. The powerful and long-lasting
inhibitory effects of diethyldithiocarbamate affect both
the first and second stages of skin tumor promotion.

 However, because the diethyldithiocarbamate is
injected intraperitoneally, it is likely that only very
20 small fractions of the doses of diethyldithiocarbamate
actually reach the target cells. Because there is a good
correlation between polyamine and DNA synthesis, there is
little doubt that the sequential induction of ornithine
decarboxylase activity and macromolecule synthesis by TPA
25 may be essential for the epithelial hyperproliferation
associated with the later stages of skin tumor promotion.
Moreover, the induction of epidermal DNA synthesis, but
not ornithine decarboxylase activity, may be necessary for
the conversion phase of skin carcinogenesis elicited when
30 TPA is used as a stage 1 promoter. Since undisturbed DNA
synthesis may be an essential component of several stages
of tumor promotion, the efficacy of diethyldithiocarbamate
against both the first and second stages of skin tumor
promotion may be linked to its ability to inhibit DNA
35 synthesis in conjunction with its antioxidant property.

 There have been many reports in the prior art
relating to the general concept of providing direct

- 5 -

transport of an agent which is toxic to tumor cells directly to tumors having β glucuronidase activity by conjugating the agent with glucuronic acid. Among such reports are Von Ardenne, M. et al., Agressologie, 1976, 5 176(5): 261-264; East German Patent No. 122,386; German Offenlegungsschrift 22 12 014; Sweeney et al., Cancer Research 31: 477-478, 1971; Baba et al., Gann, 69: 283-284; and Ball, Biochem. Pharm 23: 3171-3177 (1974).

Von Ardenne suggest broadly many types of 10 aglycones which may be conjugated to glucuronic acid and will be active at the tumor site. There include, broadly, alkylating groups, antimetabolites, cytotoxins, membrane-active (lytic) groups, glycolysis stimulators, respiration inhibitors, inorganic and organic acids and cell cycle 15 stoppers. The East German patent also suggests many such combinations, including 5-fluorouracil-glucuronide, aniline mustard-glucuronide and many others. The Offenlegungsschrift also mentions a large number of glucuronides. Sweeney et al. disclose the anti-tumor 20 activity of mycophenolic acid- β -D-glucuronides. Baba et al. note the anti-tumor activity of 5-fluorouracil-o- β -D-glucuronide, and Ball discloses the anti-tumor activity of p-hydroxyaniline mustard glucuronide.

Rubin, in U.S. Patents Nos. 4,337,760 and 25 4,481,195, discloses methods for treating tumors having high β -glucuronidase activity with glucuronides with aglycones toxic to the tumor cells with great safety toward the rest of the body by first administering an alkalinizing agent in an amount sufficient to maintain 30 the pH level of non-tumor tissues at approximately 7.4 during the glucuronide treatment to inactivate β -glucuronidase activity in the rest of the body. Thus, the toxic agent is directed only to the cancer cells, as opposed to all of the healthy cells of the body, since the 35 aglycone is only released at the cancer site. Tumors having high glucuronidase activity can be identified by assaying tumor cells obtained in a biopsy for β -

- 6 -

glucuronidase activity, or by administering a glucuronide whose aglycone has been labelled with a radioactive isotope. If upon a full body scan it is found that the radioisotope is accumulated at any specific areas of the body, this will indicate not only the location of the tumor but the fact that the tumor has sufficient β -glucuronidase activity to deconjugate the glucuronide.

Borch, in U.S. Patent No. 4,426,372, discloses that the toxicity of platinum (II) compounds used for treating tumors can be countered by administering dithiocarbamic compounds parenterally in a timely fashion. The cellular DNA is first exposed to platinum (II), and then the dithiocarbamic compound is administered. The dithiocarbamic compound is administered within six hours of platinum administration. The mode of administration of the dithiocarbamate is important, because acidic aqueous media, conjugating sugars, uronates, glycosides, liver tissue and other media or agents encountered in living biological systems can inactivate dithiocarbamic toxicity inhibitors long before the inhibitors can bind to the platinum. In addition, it has been found that alkali metal dithiocarbamates are sufficiently powerful platinum-binding compounds to dislodge the platinum from DNA/Pt(II) complexes formed in vitro.

The dithiocarbamates are also well known chelating agents for other metals such as zinc and copper.

Summary of the Invention

It is an object of the present invention to overcome the aforementioned deficiencies of the prior art.

It is an object of the present invention to provide a method and composition for treating tumor cells.

It is another object of the present invention to provide a composition and method for treating tumor cells

- 7 -

without damaging normal cells.

According to the present invention, glucuronide conjugates of thiol metal chelating agents are delivered directly to a tumor site where the β -glucuronidase present in the tumor cells cleaves the conjugate, releasing the metal chelating agent directly at the site of the tumor cell. The metal chelating compound then chelates zinc, copper or other transition metals present in the DNA locus of the cells, thus preventing cell metabolism. Without the ability to metabolize, the tumor cells die. Since undisturbed DNA synthesis may be an essential component of several stages of tumor promotion, the efficacy of the chelating agents against tumor promotion may be linked to the ability of these chelating agents to inhibit DNA synthesis.

In order to treat tumor cells successfully with the thiol chelating agents of the present invention it is essential to protect the thiol chelating agents used in the present invention from the action of bodily fluids and tissues until the chelating agent reaches the tumor site, because acidic aqueous media, conjugating sugars, uronates, glycosides, liver tissue and other media or agents encountered in living biological systems can inactivate the chelating ability of these thiol compounds, and thus their toxicity to dividing cancer cells.

The thiol compounds that can be used to chelate the necessary metals at the tumor site and thus inactivate tumor cell division have the structure



wherein R^1 and R^2 are the same or different and represent electron-donating lower aliphatic or lower cycloaliphatic radicals, i.e., radicals having fewer than 6 carbon atoms; and

M is selected from the group consisting of hydrogen, an electropositive, ionically bonded metal, and

- 8 -

the radical



5 wherein R³ and R⁴ are defined in the same manner
as R¹ and R².

Dithiocarbamic compounds have an extraordinarily
powerful capability for complexing with transition metals.
The functional group that is believed to be formed in
10 square planar complexes is
-N-CS-S-

which is believed to be one of the most stable
complexes formed. This functional group has a chelating
or ligand-forming effect which is almost impossible to
15 reverse with other chelating agents. Consequently,
dithiocarbamic compounds have the ability to substitute
for or displace or reverse most other transition metal
complexes or chelates.


Ammonias and amines, for example, are moderately
20 strong ligands in transition metal coordination complexes,
but dithiocarbamates can displace them, liberating the
free ammonia or amines. Although the present invention is
not bound by any theory, it is believed that both the
thiocarbonyl and the thiol sulfurs of the dithiocarbamic
25 functional group can form strong coordinate bonds with
transition metals. The function of the amido nitrogen in
the dithiocarbamic structure is believed to be generally
activating in nature, perhaps due to the unbonded electron
pair on the nitrogen. Accordingly, it should follow that
30 electron-donating groups substituted on the amido nitrogen
should further intensify the activity of the two sulfur
atoms. It would also be expected that electron-
withdrawing groups substituted on the nitrogen would
decrease the activity of the sulfurs.

35 Saturated and non-conjugated unsaturated
aliphatic and cycloaliphatic groups are known to have a
mild electron-donating effect and are particularly

- 9 -

suitable for substitution on the amido nitrogen of the dithiocarbamic structure. "Lower" aliphatic or cycloaliphatic radicals, in the context of the present invention, are generally considered to be those containing
5 from one to six carbon atoms. These radicals, particularly radicals having from one to three carbon atoms, do not detract significantly from the solubility of monomeric dithiocarbamic compounds in polar solvents. In addition, these groups do not introduce any acute toxicity
10 aspect to the dithiocarbamic compound.

In the case where both R¹ and R² are ethyl, i.e., diethyldithiocarbamic acid, the resulting structure has particularly low toxicity and is particularly suitable for administration to living organisms. For maximum
15 solubility in polar solvents, the preferred compounds have the structure



20 wherein R¹ and R² are as defined previously, and M is an electropositive, ionically bonded metal, which is pharmaceutically acceptable.

Structures of this type, when cleaved from the glucuronide conjugate, can dissociate into the
25 corresponding dithiocarbamate ion and an M⁺ cation in aqueous media, and thus are particularly useful for delivery to a tumor site. Accordingly, pharmaceutically acceptable cations such as the alkali metal cations, particularly sodium and potassium, are preferred.

30 Dithiocarbamates and related compounds have been reviewed extensively with respect to their chelating ability in a work by G.D. Thorn et al. entitled "The Dithiocarbamates and Related Compounds," Elsevier, New York, 1962. In addition, diethyldithiocarbamate has been
35 successfully used in analytical techniques for measuring Pt(II) in urine, Borch et al., Analytical Letters B12:917 (1979). It is also known that diethyldithiocarbamate


- 10 -

salts can reverse the coordination in various coordinate complexes of transition metals, cf. Sundermann in Ann. Clin. Res. 3: 182 (1971).

Glucuronides of diethyldithiocarbamic acid are known to be formed biosynthetically in broken- and intact-cell preparations of mouse liver, Dutton et al., Biochem. J. 129, 539-550, 1972. Additionally, Gessner et al., in Biochemical Pharmacology 21: 219- 230, 1972, disclose that the glucuronide conjugate of diethyldithiocarbamate is the major urinary metabolite of diethyldithiocarbamate, accounting for about 30% of the metabolic products captured in the urine. However, these substances have never been synthesized or otherwise prepared in pure form.

The thioglucuronides can be synthesized by the following reaction:

UDP-glucuronyltransferase



20

Alternatively, the conjugates can be prepared by the methods disclosed in Rubin, U.S. Patent No. 4,481,195 and Rubin, U.S. Patent No. 4,424,348, the entire contents of both of which are incorporated by reference.

For example, the thiols are conjugated to glucuronic acid by conjugation of the thiol with methyl(tri-O-acetyl- α -D-glucopyranosyl bromide)-uronate, which is the active form of glucuronic acid, and may be produced in accordance with the teachings of Bollenback, et al., J. Am. Chem. Soc. 77: 3310, 1955.

The thiol is introduced to the methyl(tri-O-acetyl- α -D-glucopyranosyl)bromide uronate in a solution of the thiol catalyzed by a small catalytic amount of silver oxide. There may also be used, as solvent, quinoline, methyl nitrile or methyl cyanide. Silver carbonate may also be used as the catalyst. This method yields the tri-acetyl conjugate, which has been found to be particularly

- 11 -

useful because the acetyl groups are not easily removed, so that the triacetylated compounds are even less toxic to normal cells than the free acid form of the conjugates.

Another method of condensation is to use sodium
5 or potassium hydroxide as the condensing agent in aqueous acetone solution. A stoichiometric excess of the thiol is preferably used. The reaction solution is maintained at room temperature for 24 hours or until the reaction is complete:

10 The acid is produced by reaction of the triacetyl methyl ester obtained above with a 1/2 molar amount of 0.5 N barium hydroxide which is added slowly to this solution to form a white precipitate. Preferably, an excess of barium hydroxide is added until there is no more
15 precipitation.

The addition of 0.5 N sulfuric acid, volume to volume, followed by cooling in ice water for 20 minutes, releases the free glucuronides.

The mixture is then filtered, and the
20 supernatant is dried in vacuum and crystallized from ether.

These conjugates are readily hydrolyzed by β -glucuronidase to release the thiol chelating compound at the site of the β -glucuronidase active tumor by the
25 action of the enzyme on the conjugate.

The triacetylated form of the glucuronide is the preferred form of the compounds to be used in accordance with the present invention. However, in addition to the free acid form of the conjugate, other pharmaceutically
30 acceptable esters may be used, although in most cases it would be expected that their activity would be somewhat less due to their relatively lower affinity to β -glucuronidase. Therefore, whenever the term "glucuronide compound" is used in the present specification and claims,
35 it is understood to include not only the free glucuronic acid form of the conjugate but also pharmaceutically

- 12 -

acceptable salts and esters thereof as discussed hereinabove.

The triacetylated form of the conjugate is the preferred form to use, as the acetylation provides an additional safety factor for normal cells in the body. These acetyl groups are not easily removed, so that the triacetylated conjugates are not particularly cytotoxic to normal cells. However, since primitive cells, such as growing cancer cells, can produce many different types of enzymes, including acetylase, these primitive cells can readily remove the acetyl groups on the acetylated conjugates to provide active forms of the compound directly at the site of a growing tumor. The tri-acetylated conjugates are lipid soluble and are retained by the body at the tumor site for a much longer period of time than the free acid form of the conjugates. The tri-acetylated conjugates have also been found able to cross the blood-brain barrier, so that they can be used for treating tumors having β -glucuronidase activity in the brain.

The reason that the tri-acetylated conjugates are particularly useful for treating tumor cells is because primitive cells can produce acetylase along with a great variety of other enzymes, and this acetylase removes the acetyl groups from the conjugate. The more anaplastic (more immature) the tumor cells, the more enzymes they produce, so that the triacetylated form of the conjugated drug is more selectively toxic to tumor cells than even the conjugated acid form. Thus, since two steps are required to liberate the cytotoxic compound, the acetylated conjugates are even more preferentially delivered to the site of an active tumor than are the acid form of the conjugates.

The selectivity of glucuronide compounds toward tumors can be greatly increased and the possible deconjugation of the toxic aglycones in healthy parts of the body can be greatly minimized by administering to the

- 13 -

patient, prior to or simultaneously with administration of the glucuronide, an alkalinizing agent which will maintain the pH of the rest of the body at a pH of about 7.4. It is known that the activity of β -glucuronidase activity is substantially nil at a pH of about 7.4. Thus, the administration of alkalinizing agents such as bicarbonates or other basic salts will substantially decrease and eliminate β -glucuronidase activity which occurs naturally in certain healthy tissues such as the kidneys, spleen and liver. Such an administration of alkalinizing agent will not diminish the acidity of the tumor cells themselves, however, in view of the naturally low pH of the tumor cells, the mechanism of prior hyperacidification and the lack of substantial blood perfusion through the tumor area, as well as other possible mechanisms. It has been suggested in the literature, in fact, that bicarbonate will actually increase the acidity of the cancer cells, cf. Gullino et al., J.N.C.I. 34 (6): 857-869, 1965.

Since the β -glucuronidase activity of the tumor cells is enhanced by acidification, and the β -glucuronidase activity of the rest of the body, particularly of the kidneys, will be substantially eliminated by alkalinization, the cytotoxic thiols will only be released at the tumor site itself due to deconjugation of the glucuronides by the action of β -glucuronidase. Without the alkalinization step, substantial amounts of toxic materials may be released, for example in the kidneys, and the cytotoxic thiols so released may cause substantial damage to these organs. Thus, only through the use of the present invention can glucuronides of thiol chelating compounds which are toxic to tumor cells be used with a great degree of safety and efficacy. The greater the toxicity of the thiol chelating compounds, the more important is the alkalinization step. Use of the triacetylated form of the conjugates provides an additional degree of safety for normal cells, as only

- 14 -

the tumor cells produce sufficient acetylase to liberate the free acid conjugate.

Other steps for increasing β -glucuronidase activity at the tumor cells may also be undertaken. One
5 method of accomplishing this is to elevate the temperature of the toxic cells at the time of treatment. This may be done by elevating the temperature of the entire body such as by use of a pyrogenic drug or by elevating the
10 temperatures solely in the area of the toxic cells, such as by microwave radiation or electrical current. Raising of the temperature increases β -glucuronidase activity, thereby increasing the efficiency of the deconjugation of the glucuronides. It is known that an elevation of body temperature of 3°C increases β -glucuronidase activity by
15 50%.

Known pyrogenic drugs include etiocholanolone, progesterone, dinitrophenol, dinitrocresol, and the like. Because dinitrophenol and dinitrocresol are also
20 cytotoxic, the use of these compounds are preferred, particularly when they are administered as the glucuronide.

Local hyperthermia in the region of suspected tumor cells is preferred to general hyperthermia, because
25 general hyperthermia will also increase the β -glucuronidase activity in healthy cells. However, because of the alkalization step, this is not a major problem. If the hyperthermia is local, then this provides an additional degree of certainty that the glucuronides will only become deconjugated at the tumor site. The
30 application of microwave treatment directed at the suspected tumor site is one way to achieve total hyperthermia. Due to the different electrical resistance of tumor cells, another method of achieving some degree of local hyperthermia is by administering a low electrical
35 current through the body.

A further manner of increasing β -glucuronidase activity selectively at tumor cells is by administration

- 15 -

of estrogen to female patients or testosterone to male patients, for tumors which are not estrogen- or testosterone-dependent. It has been reported that these compounds induce β -glucuronidase activity in
5 trophoblastic cells. Since certain tumor cells are known to be trophoblastic, this method is particularly useful for those types of cells. The alkalization step would prevent damage to healthy trophoblastic cells.

Before treatment of patients in accordance with
10 the present invention, it should be ascertained that the particular type of tumor involved has a high β -glucuronidase activity. This may be done in a number of ways. One way is to assay tumor cells obtained in a biopsy for β -glucuronidase activity. If such a test is
15 positive, then the pharmaceutical compositions of the present invention may be administered.

A second method is the administration of a glucuronide whose aglycone has been labelled with a radioactive isotope. If, upon a full body scan, it is
20 found that the radioisotope is accumulated at any specific areas of the body, then this will indicate not only the location of the tumor but the fact that the tumor has sufficient β -glucuronidase activity to deconjugate the glucuronide. If there are no tumors present, or if the
25 tumors are of the type which do not have β -glucuronidase activity, then there will be no accumulation of radioisotope in the body as the alkalization step of the present invention eliminates all β -glucuronidase activity and the isotope will be passed through the body.

30 Another method of diagnosing tumors which are treatable by means of the present invention is to test for the presence of free glucuronic acid in the urine. While the presence of glucuronides in the urine is common, the presence of free glucuronic acid in the urine, and
35 particularly the presence of increasing amounts of glucuronic acid when tested over a period of several days, is a potent indication of the presence of tumors with β -

- 16 -

glucuronidase activity. It is hypothesized that the presence of free glucuronic acid in the urine in cancer patients is caused by the action of β -glucuronidase in the cancer cells on the intercellular filaments and
5 connective tissue. Glucuronic acid is a reaction product of such activity because the intercellular filaments and connective tissues are composed of polymers of which glucuronic acid is an element and which are known substrates for the enzyme β -glucuronidase.

10 Free glucuronic acid can readily be distinguished from conjugated glucuronides in the urine. Both glucuronides and glucuronic acid give a chromogenic complex with tetraborate in concentrated sulfuric acid, which complex reacts with m-hydroxydiphenyl to create a
15 colored water-soluble complex. When lead acetate is added at an alkaline pH, the glucuronides precipitate and the addition of dithizone (dithiosemicarbazone) makes a stable complex with the excess lead. Accordingly, an optical reading may be taken representative of the amounts of
20 total glucuronides and free glucuronic acid after tetraborate and m-hydroxydiphenyl have been added. A second reading may then be taken after the conjugated glucuronides and excess lead have been removed from the aqueous phase by the addition of basic lead acetate and
25 after dithizone has been added. Alternatively, the conjugated glucuronides can be removed by reaction with barium hydroxide. The addition of barium hydroxide to the urine sample will cause precipitation of the conjugated glucuronides but not of the free glucuronic acid. After
30 centrifugation and filtration the conjugated glucuronides are eliminated and what remains is only the free glucuronic acid. A reading representative of the amount of free glucuronic acid may then be taken. The alternative procedure bypasses the necessity of the use of
35 dithizone.

In the urine test for glucuronidase activity, normal patients exhibit between 200 and 400 mg per 24

- 17 -

hours of free glucuronic acid in the urine. Cancer patients with well developed tumors which have β -glucuronidase activity show greater than 200 to 7000 mg per 24 hours free glucuronic acid. Accordingly, using
5 this above test, if more than about 400 mg per 24 hours of free glucuronide is exhibited, this is an excellent indication of the presence of tumors having a high β -glucuronidase activity.

A negative indication on this urine test will
10 not conclusively rule out the presence of tumors having β -glucuronidase activity, because tumors in their initial stages, although they might have β -glucuronidase activity, might not release sufficient free glucuronic acid to cause a positive reading of the urine. Therefore,
15 the urine test should be repeated, and if an increasing amount of free glucuronic acid is found, then this is another indication of the presence of a tumor having β -glucuronidase activity.

Once it has been determined that the patient has
20 a tumor having β -glucuronidase activity, the first step of the treatment is to administer a dose of glucose as, for example 100 g of honey, glucose, or other simple sugar. Approximately one hour later, an intravenous drip is begun of a solution in distilled water containing
25 approximately 10% glucose and 60 milliequivalents sodium bicarbonate. Approximately 1 liter is administered, assuming no contraindications, and the pH of the urine is checked to determine that it has reached a pH of approximately 7.4. This will establish that the system
30 has become alkalinized and it is now safe to administer the glucuronide. Another liter of the same glucose-bicarbonate solution, but also including the desired amount of glucuronide, is then administered. This is repeated daily as needed.

35 If there are contraindications for the administration of bicarbonate, then an antacid may be orally administered. This antacid may be any conventional

- 18 -

antacid such as sodium bicarbonate, magnesium bicarbonate, aluminum hydroxide, aluminum magnesium silicate, magnesium carbonate, magnesium hydroxide, magnesium oxide, or the like. The important criterion is that the pH of the urine become approximately 7.4 and remain so during treatment.

The hyperacidification of the tumor cells is caused by a hyperglycemic condition in the patient. Therefore, any hyperglycemic agent may be used as the hyperacidification agent, as, for example, fructose, galactose, lactose or glucagon. Furthermore, it should be understood that this hyperglycemic condition may be effected in any known manner. For example, if the patient is diabetic, then the condition can be brought about by decreasing the insulin administration.

Any agent which will raise the pH of the urine to approximately 7.4 can be used as the alkalinizing agent, including sodium or potassium bicarbonate or citrate, or other basic salts or antacids. While it is preferred that these agents be administered intravenously, they may be administered orally.

When the term "approximately 7.4" is used in the present specification and claims, with respect to the pH level to be maintained in the rest of the body, it should be understood that a pH level slightly above or below 7.4 may be used, although this is not preferred. As the pH decreases from 7.4, the β -glucuronidase activity increases until the optimal pH is reached. Furthermore, below pH 7.0 the rest of the body will not be alkaline but will be acid. Above 7.4 the danger of alkalosis increases without any substantial further decrease in β -glucuronidase activity. A pH level of 7.4 is preferred, as this is physiological pH and cannot be harmful to the body, and it is known that the β -glucuronidase activity in healthy organs is substantially nil at this pH level.

The dosage of the compounds administered should be monitored to avoid any side effects due to the massive

- 19 -

release of toxins caused by the dying cancer cells. It may be preferable to treat the patient with the conjugates of the present invention in short courses of several days, leaving several days in between to allow any toxins
5 released by the dying cancer cells to leave the body before continuing with treatment.

Besides intravenous administration, the glucuronide conjugates of the present invention may be administered by any means of parenteral administration.
10 However, the glucuronides in the free acid form should not be administered orally, as it is known that β -glucuronidase is present in the digestive tract, and therefore would destroy the conjugates and release the toxic thiol before it reached the site of the cancer.
15 However, the acetylated form of the conjugates can be administered orally, since this form requires acetylase to liberate the free acid form and there is insufficient acetylase in the normal gastrointestinal tract to liberate the free acid form of the conjugate.

20 The amount of glucuronide conjugate to be administered to any given patient must be determined empirically and will differ depending upon the condition of the patient. Relatively small amounts of the compounds can be administered at first, with steadily increasing
25 dosages if no adverse effects are noted. Of course, the maximum safe toxicity dosage as determined in routine animal toxicity tests should never be exceeded.

Optimally, the concentration of glucuronide conjugate to be administered may be sufficient to
30 administer a concentration of thiol chelating compound from about 10 mg/kg body weight to about 2000 mg/kg body weight.

It is clear that any tumor cells having β -glucuronidase activity may be treatable in accordance with
35 the present invention, with the remaining organs of the body being protected by the alkalization step. Tumors which are known to have β -glucuronidase activity include

- 20 -

solid breast tumors and their metastases, bronchogenic carcinoma and its metastases, and lymphomas.

It is also known that neoplasms which do not have high β -glucuronidase activity, and therefore cannot be treated in accordance with the present invention, include leukemias. It must be understood, however, that these lists are not meant to be complete, and that the prior art is aware of many other tumors that have β -glucuronidase activity. However, whether or not the art is presently aware that any given tumor has β -glucuronidase activity, this can be determined by any of the various methods of diagnosis discussed in the present specification. If it is determined that the tumor does indeed have β -glucuronidase activity, the therapeutic treatment of the present invention can be effectively used.

When it is desired to induce hyperthermia to increase β -glucuronidase activity, a method should be selected by which the temperature is raised as much as possible without risking damage to healthy portions of the body, such as the eyes. An increase of about 2°C for whole body hyperthermia and as much as 4.5°C for local hyperthermia is preferred. The hyperthermia should be timed to last about an hour at the time of greatest glucuronide concentration at the tumor site. For example, when local microwave treatment is selected, it should begin about one half hour after commencement of the intravenous conjugate drip and be continued for about one hour. The proper dosage of known pyrogens to achieve the desired degree of hyperthermia would be known to those skilled in the art, or could be easily empirically determined. A dosage of about 30 mg/day of dinitrophenol, for example, would be appropriate.

When estrogen or testosterone are to be administered, a dosage of 5-15 mg/body weight/day would provide the desired inducement of β -glucuronidase activity.

- 21 -

To treat patients suffering from cancers which exhibit β glucuronidase activity, the dithiocarbamates are administered in the form of acetylated glucuronic acid conjugates or other forms of glucuronic acid conjugates, including the free acid conjugates or salts of the free acid or other esters of glucuronic acid conjugates. Capsules are formulated, generally containing approximately 0.6 gram/capsule of active ingredient. Generally, five capsules three times daily, providing nine grams/day of active ingredient are administered. The patient's serum is measured after a loading dosage is administered of the compound to maintain a level of approximately 1 mM of compound in the serum.

The conjugates of the present invention can be administered to patients suffering from β -glucuronidase-dependent cancers at doses ranging from about 1-15 grams/day of total dosage. Although it has been found that maintaining a serum level of about 1 mM of conjugate is desirable, serum levels ranging from about 0.1 mM to about 10 mM can be used, depending upon the patient's response to the treatment.

The conjugates of the present invention can be combined with a pharmaceutically acceptable carrier therefore, and optionally other therapeutic and/or prophylactic ingredients. The carriers must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical formulations suitable for oral administration wherein the carrier is a solid are most preferably presented as unit dose formulations such as boluses, capsules, and the like, as well as sachets or tablets each containing a predetermined amount of the active ingredient. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active conjugate in

- 22 -

a free-flowing form, such as a powder or granules optionally mixed with a binder, lubricant, interdiluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding the active conjugate with
5 an inert liquid diluent. Tablets may be optionally coated and, if uncoated, may optionally be scored. Capsules may be prepared by filling the active conjugate, either alone or in admixture with one or more accessory ingredients, into the capsule cases and then sealing them
10 in the usual manner. Cachets are analogous to capsules wherein the active conjugate together with any optional accessory ingredient is sealed in a rice paper envelope.

Pharmaceutical formulations suitable for oral administration in which the carrier is a liquid may
15 conveniently be presented as a solution in an aqueous liquid or a non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.

Pharmaceutical formulations suitable for parenteral administration are conveniently presented in
20 unit dose or multi-dose container which are sealed after introduction of the formulation until required for use.

It should be understood that in addition to the aforementioned carrier ingredients the pharmaceutical formulations described above may include, as appropriate,
25 one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface active agents, thickeners, lubricants, preservative (including anti-oxidants) and the like, and substances included for the purpose of rendering the formulation
30 isotonic with the blood of the intended recipient.

The pharmaceutical formulations may be any formulation in which the active compound may be administered and include those suitable for oral or parenteral (including intramuscular and intravenous)
35 administration. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of

- 23 -

pharmacy. All of the methods include the step of bringing
into association the active compound with liquid carriers
or finely divided solid carriers of both and then, if
necessary, shaping the product into the desired
5 formulation.

The foregoing description of the specific
embodiments will so fully reveal the general nature of the
invention that others can, by applying current knowledge,
readily modify and/or adapt for various applications such
10 specific embodiments without departing from the generic
concept, and therefore such adaptations and modifications
are intended to be comprehended within the meaning and
range of equivalents of the disclosed embodiments. It is
to be understood that the phraseology or terminology
15 herein is for the purpose of description and not of
limitation.

20

25

30

35

- 24 -

WHAT IS CLAIMED IS

1. A method for selectively treating tumor cells which have β -glucuronidase activity to inhibit the metabolism of said tumor cells comprising administering to a patient suffering from said tumor cells an effective amount of a conjugate made by conjugating glucuronic acid or a pharmaceutically acceptable ester or salt thereof to a thiol chelating compound of the formula:



wherein R^1 and R^2 are selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloaliphatic groups, and M is selected from the group consisting of hydrogen, an electropositive, ionically bonded pharmaceutically acceptable metal, and the radical



wherein R^3 and R^4 are selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloaliphatic groups.

2. The method according to claim 1 wherein the conjugate is formed from the triacetylated form of glucuronic acid.

3. The method according to claim 2 wherein the conjugate is administered orally.

4. The method according to claim 1 wherein the thiol chelating compound is selected from the group consisting of diethyldithiocarbamate and pharmaceutically acceptable salts thereof.

5. The method according to claim 1 wherein, prior to administration of said conjugate, the patient is administered an alkalinizing agent in an amount sufficient to maintain the pH level of the non-tumor tissues of the patient at approximately 7.4 during the treatment with said conjugate.

- 25 -


6. The method according to claim 1 wherein, prior to administering said conjugate, the tumor cells are hyperacidified.

7. The method according to claim 1 further including the step of inducing hyperthermia at least at the site of the tumor being treated to an extent sufficient to increase substantially β -glucuronidase activity at the site without substantially affecting the overall health of the patient at the time of maximum conjugate concentration at the tumor.

8. The method according to claim 7 wherein said hyperthermia is induced locally at the tumor by administration of the glucuronide of a pyrogen, by microwave treatment or by passage of electrical current through the body.

9. The method according to claim 1 further including the step of administering estrogen or testosterone substantially simultaneously with administration of said conjugate, wherein the tumor is not estrogen- or testosterone-dependent.

10. A composition for selectively treating tumor cells which have β -glucuronidase activity comprising a pharmaceutically acceptable carrier and an effective amount of a conjugate made by conjugating a glucuronide compound selected from the group consisting of glucuronic acid and pharmaceutically acceptable esters and salts thereof to a thiol chelating compound of the formula:



wherein R^1 and R^2 are selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloaliphatic groups, and M is selected from the group consisting of hydrogen, an electropositive, ionically bonded pharmaceutically

- 26 -

acceptable metal, and the radical



5 wherein R³ and R⁴ are selected from the group
consisting of C₁-C₆ alkyl and C₃-C₆ cycloaliphatic
groups.

11. The composition according to claim 10
wherein the glucuronide compound is a triacetylated
10 glucuronic acid.

12. The composition according to claim 11
wherein the glucuronide compound is methyl-(tri-O-acetyl-
α-D-glucopyranosyl)bromide uronate.

13. The composition according to claim 10
15 wherein the thiol chelating compound is selected from the
group consisting of diethyldithiocarbamate and
pharmaceutically acceptable salts thereof.

14. The composition according to claim 10
wherein the carrier is suitable for parenteral
20 administration.

15. The composition according to claim 11
wherein the carrier is suitable for oral administration.

16. The method according to claim 1 wherein the
tumor cells are selected from the group consisting of
25 solid breast tumors, bronchogenic carcinoma, and
lymphomas.

17. The method according to claim 16 wherein
the tumor cells are solid breast tumors.

18. The method according to claim 1 wherein the
30 conjugate is administered in sufficient amount to provide
from about 19 mg/kg body weight to about 2000 mg/kg body
weight of the thiol chelating compound.

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/01237

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(5) :A61K 31/095, 49/00
 US CL :514/23, 476, 483, 883
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 514/23, 476, 483, 883

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,327,074 (Rubin et al.) 27 April 1982, see entire document.	1-18
A	US, A, 4,337,760 (Rubin) 06 July 1982, see entire document.	1-18
A	US, A, 4,424,348 (Rubin) 03 January 1984, see entire document.	1-18
A	US, A, 4,426,372 (Borch) 17 January 1984, see entire document.	1-18
A	US, A, 4,481,195 (Rubin) 06 November 1984, see entire document.	1-18

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 23 APRIL 1993	Date of mailing of the international search report 05 MAY 1993
--	--

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer RONALD W. GRIFFIN Telephone No. (703) 308-0196
---	---

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/01237

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,584,368 (Rubin) 22 April 1986, see entire document.	1-18
A	US, A, 4,645,661 (Schonbaum) 24 February 1987, see entire document.	1-18
A	US, A, 4,762,705 (Rubin) 09 August 1988, see entire document.	1-18
A	US, A, 4,895,874 (Rubin et al.) 23 January 1990, see entire document.	1-18
A	US, A, 5,002,755 (Mitchell et al.) 26 March 1991, see entire document.	1-18
A	US, A, 5,005,588 (Rubin) 09 April 1991, see entire document.	1-18
A	US, A, 5,035,878 (Borch et al.) 30 July 1991, see entire document.	1-18